Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the clinical efficacy and safety of S-488410 for
advanced non-small cell lung cancers who failed to standard therapy.
The investigators previously identified three novel HLA-A*2402-restricted epitope peptides,
which were derived from three cancer-testis antigens, as targets for cancer vaccination
against lung cancer. In this phase II trial, we examine using a combination of these three
peptides the safety, immunogenicity, and antitumor effect of vaccine treatment for
HLA-A*2402-positive advanced small cell lung cancer patients who failed to standard therapy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluation of difference in overall survival after vaccination therapy between HLA-A 24:02 and non-HLA-A 24:02 patients.
Participants will be followed for the duration of vaccination therapy, an expected average of more than 1 year.
Yataro Daigo, MD, PhD
Department of Medical Oncology, Shiga University of Medical Science
Japan: Ministry of Health, Labor and Welfare